CoChat

Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge

Open access
Erritzoe, David, Godlewska, Beata R., Rizzo, Gaia, Searle, Graham E., Agnorelli, Claudio, Lewis, Yvonne, Ashok, Abhishekh H., Colasanti, Alessandro, Boura, Iro, Farrell, Chloe, Parfitt, Hollie, Howes, Oliver, Passchier, Jan, Gunn, Roger N., Politis, Marios, Nutt, David J., Cowen, Philip J., Knudsen, Gitte M., Rabiner, Eugenii A. · 2023 · Biological Psychiatry
Cited by 90

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND The serotonin hypothesis of depression proposes that diminished serotonergic (5-HT) neurotransmission is causal in the pathophysiology of the disorder. Although the hypothesis is over 50 years old, there is no firm in vivo evidence for diminished 5-HT neurotransmission. We recently demonstrated that the 5-HT2A receptor agonist positron emission tomography (PET) radioligand [11C]Cimbi-36 is sensitive to increases in extracellular 5-HT induced by an acute d-amphetamine challenge. Here we applied [11C]Cimbi-36 PET to compare brain 5-HT release capacity in patients experiencing a major depressive episode (MDE) to that of healthy control subjects (HCs) without depression. METHODS Seventeen antidepressant-free patients with MDE (3 female/14 male, mean age 44 ± 13 years, Hamilton Depression Rating Scale score 21 ± 4 [range 16-30]) and 20 HCs (3 female/17 male, mean age 32 ± 9 years) underwent 90-minute dynamic [11C]Cimbi-36 PET before and 3 hours after a 0.5-mg/kg oral dose of d-amphetamine. Frontal cortex (main region of interest) 5-HT2A receptor nondisplaceable binding was calculated from kinetic analysis using the multilinear analysis-1 approach with the cerebellum as the reference region. RESULTS Following d-amphetamine administration, frontal nondisplaceable binding potential (BPND) was significantly reduced in the HC group (1.04 ± 0.31 vs. 0.87 ± 0.24, p < .001) but not in the MDE group (0.97 ± 0.25 vs. 0.92 ± 0.22, not significant). ΔBPND of the MDE group was significantly lower than that of the HC group (HC: 15% ± 14% vs. MDE: 6.5% ± 20%, p = .041). CONCLUSIONS This first direct assessment of 5-HT release capacity in people with depression provides clear evidence for dysfunctional serotonergic neurotransmission in depression by demonstrating reduced 5-HT release capacity in patients experiencing an MDE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2022.10.012

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 51

  1. Delgado, 2006, Monoamine depletion studies: Implications for antidepressant discontinuation syndrome, J Clin Psychiatry, 67, 22
  2. Shaw, 1967, 5-Hydroxytryptamine in the hind-brain of depressive suicides, Br J Psychiatry, 113, 1407, 10.1192/bjp.113.505.1407 · DOI · Paper page
  3. Cowen, 2015, What has serotonin to do with depression?, World Psychiatry, 14, 158, 10.1002/wps.20229 · DOI · Paper page
  4. Artigas, 2002, Mechanism of action of antidepressants, Psychopharmacol Bull, 36, 123
  5. Shopsin, 1975, Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients, Psychopharmacol Commun, 1, 239
  6. Shopsin, 1976, Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients, Arch Gen Psychiatry, 33, 811, 10.1001/archpsyc.1976.01770070041003 · DOI · Paper page
  7. Smith, 1997, Relapse of depression after rapid depletion of tryptophan, Lancet, 349, 915, 10.1016/S0140-6736(96)07044-4 · DOI · Paper page
  8. Delgado, 1999, Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action, Biol Psychiatry, 46, 212, 10.1016/S0006-3223(99)00014-1 · DOI · Paper page
  9. Dan, 2017, Separate neural representations of depression, anxiety and apathy in Parkinson’s disease, Sci Rep, 7, 10.1038/s41598-017-12457-6 · DOI
  10. Pagano, 2017, Serotonin transporter in Parkinson’s disease: A meta-analysis of positron emission tomography studies, Ann Neurol, 81, 171, 10.1002/ana.24859 · DOI
  11. Braak, 2003, Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 · DOI · Paper page
  12. Jørgensen, 2021, Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study, J Cereb Blood Flow Metab, 41, 1954, 10.1177/0271678X20982389 · DOI
  13. Moncrieff, 2022, The serotonin theory of depression: A systematic umbrella review of the evidence [published online Jul 20], Mol Psychiatry
  14. Finnema, 2015, Application of cross-species PET imaging to assess neurotransmitter release in brain, Psychopharmacology, 232, 4129, 10.1007/s00213-015-3938-6 · DOI · Paper page
  15. Shotbolt, 2012, Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans, J Cereb Blood Flow Metab, 32, 127, 10.1038/jcbfm.2011.115 · DOI · Paper page
  16. Erritzoe, 2020, Serotonin release measured in the human brain: A PET study with [(11)C]CIMBI-36 and d-amphetamine challenge, Neuropsychopharmacology, 45, 804, 10.1038/s41386-019-0567-5 · DOI
  17. Heal, 1998, A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents, Br J Pharmacol, 125, 301, 10.1038/sj.bjp.0702067 · DOI · Paper page
  18. Yang, 2018, Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain, Transl Psychiatry, 8, 132, 10.1038/s41398-018-0178-7 · DOI
  19. Kehr, 2011, Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats, Br J Pharmacol, 164, 1949, 10.1111/j.1476-5381.2011.01499.x · DOI · Paper page
  20. Nejati, 2021, The role of dorsolateral and ventromedial prefrontal cortex in the processing of emotional dimensions, Sci Rep, 11, 1971, 10.1038/s41598-021-81454-7 · DOI · Paper page
  21. Hamilton, 1967, Development of a rating scale for primary depressive illness, Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI · Paper page
  22. Ichise, 2002, Strategies to improve neuroreceptor parameter estimation by linear regression analysis, J Cereb Blood Flow Metab, 22, 1271, 10.1097/01.WCB.0000038000.34930.4E · doi:10.1097/01.wcb.0000038000.34930.4e · Paper page
  23. Tukey, 1977, Some thoughts on clinical trials, especially problems of multiplicity, Science, 198, 679, 10.1126/science.333584 · DOI · Paper page
  24. Beliveau, 2017, A high-resolution in vivo atlas of the human Brain’s serotonin system, J Neurosci, 37, 120
  25. Toll, 1998, Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications, NIDA Res Monogr, 178, 440
  26. Tyacke, 2015, Optimising PET approaches to measuring 5-HT release in human brain, Synapse, 69, 505, 10.1002/syn.21835 · DOI
  27. Johnson, 2011, The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder, Neuropsychopharmacology, 36, 2139, 10.1038/npp.2011.105 · DOI
  28. Savitz, 2013, Neuroreceptor imaging in depression, Neurobiol Dis, 52, 49, 10.1016/j.nbd.2012.06.001 · DOI · Paper page
  29. Fukui, 2007, Vmat2 heterozygous mutant mice display a depressive-like phenotype, J Neurosci, 27, 10520, 10.1523/JNEUROSCI.4388-06.2007 · DOI · Paper page
  30. Taylor, 2009, Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity, J Neurosci, 29, 8103, 10.1523/JNEUROSCI.1495-09.2009 · DOI · Paper page
  31. Narboux-Nême, 2011, Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: Neural and behavioral consequences, Neuropsychopharmacology, 36, 2538, 10.1038/npp.2011.142 · DOI
  32. Bhagwagar, 2004, Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635, Mol Psychiatry, 9, 386, 10.1038/sj.mp.4001401 · DOI · Paper page
  33. Sullivan, 2009, Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression, Biol Psychiatry, 66, 223, 10.1016/j.biopsych.2009.01.028 · DOI · Paper page
  34. Ballanger, 2012, Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease, Mov Disord, 27, 84, 10.1002/mds.23895 · DOI
  35. Erritzoe, 2010, A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: An in vivo molecular imaging study in humans, J Neurosci, 30, 3391, 10.1523/JNEUROSCI.2852-09.2010 · DOI · Paper page
  36. Bhagwagar, 2006, Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: A positron emission study with [(11)C]MDL 100,907, Am J Psychiatry, 163, 1580, 10.1176/ajp.2006.163.9.1580 · DOI · Paper page
  37. Biver, 1997, Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex, Br J Psychiatry, 171, 444, 10.1192/bjp.171.5.444 · DOI · Paper page
  38. Attar-Lévy, 1999, The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine, Biol Psychiatry, 45, 180, 10.1016/S0006-3223(98)00007-9 · DOI
  39. Yatham, 2000, Brain serotonin2 receptors in major depression: A positron emission tomography study, Arch Gen Psychiatry, 57, 850, 10.1001/archpsyc.57.9.850 · DOI · Paper page
  40. Mintun, 2004, Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: In vivo measurement with [18F]altanserin positron emission tomography, Biol Psychiatry, 55, 217, 10.1016/j.biopsych.2003.08.015 · DOI · Paper page
  41. Messa, 2003, 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: A PET study, Psychopharmacology, 167, 72, 10.1007/s00213-002-1379-5 · DOI
  42. Meyer, 1999, Prefrontal cortex 5-HT2 receptors in depression: An [18F]setoperone PET imaging study, Am J Psychiatry, 156, 1029, 10.1176/ajp.156.7.1029 · DOI · Paper page
  43. Frokjaer, 2010, Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding, Neuropsychopharmacol, 35, 1129, 10.1038/npp.2009.218 · DOI · Paper page
  44. Elmenhorst, 2012, Sleep deprivation increases cerebral serotonin 2A receptor binding in humans, Sleep, 35, 1615, 10.5665/sleep.2230 · DOI · Paper page
  45. Soloff, 2010, Gender, personality, and serotonin-2A receptor binding in healthy subjects, Psychiatry Res, 181, 77, 10.1016/j.pscychresns.2009.08.007 · DOI · Paper page
  46. Samama, 1993, A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model, J Biol Chem, 268, 4625, 10.1016/S0021-9258(18)53442-6 · DOI · Paper page
  47. Roberts, 2005, Mechanisms of inverse agonist action at D2 dopamine receptors, Br J Pharmacol, 145, 34, 10.1038/sj.bjp.0706073 · doi:10.1038/sj.bjp.0706073
  48. Narendran, 2006, Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo, Synapse, 60, 485, 10.1002/syn.20325 · DOI · Paper page
  49. Leonhardt, 1992, Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors, Mol Pharmacol, 42, 328, 10.1016/S0026-895X(25)08918-7 · DOI · Paper page
  50. Teitler, 1990, 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: Evidence for multiple states and not multiple 5HT2 receptor subtypes, Mol Pharmacol, 38, 594, 10.1016/S0026-895X(25)09516-1 · DOI · Paper page
  51. Egan, 2000, Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors, Synapse, 35, 144, 10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K · DOI · Paper page

Cited by

See all 90

Metadata

Authors
Erritzoe, D., Godlewska, B. R., Rizzo, G., Searle, G. E., Agnorelli, C., Lewis, Y., Ashok, A. H., Colasanti, A., Boura, I., Farrell, C., Parfitt, H., Howes, O., Passchier, J., Gunn, R. N., Politis, M., Nutt, D. J., Cowen, P. J., Knudsen, G. M., & Rabiner, E. A.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2023-06
Volume
93
Issue
12
Pages
1089-1098
ISSN
0006-3223 (ISSN-L)
OpenAlex
W4307820930
Cited by
90
References
16
FWCI
7.03
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Innovationsfonden (17/EE/0484, 4108-00004B)
  • Medical Research Council (MR/K022202/1)
  • Michael J. Fox Foundation for Parkinson's Research
  • University of Exeter
  • Eli Lilly and Company
  • King's College London
  • CHDI Foundation
  • European Commission
  • King’s College London

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge. https://app.cochat.ai/papers/10.1016/j.biopsych.2022.10.012
The paper
Erritzoe, D., Godlewska, B. R., Rizzo, G., Searle, G. E., Agnorelli, C., Lewis, Y., Ashok, A. H., Colasanti, A., Boura, I., Farrell, C., Parfitt, H., Howes, O., Passchier, J., Gunn, R. N., Politis, M., Nutt, D. J., Cowen, P. J., Knudsen, G. M., & Rabiner, E. A. (2023). Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2022.10.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.